Vaccine leader in a quarter skyrocketed 10 billion, the future prospects of the biomedical industry?

This time we have all seen on the network such a very shocking news, that is, the vaccine leader in a quarter skyrocketed 10 billion trillion in assets, in the late night inside the crazy high, many investors said this is very shocked, but at the same time also very optimistic about the future prospects of the biomedical industry, feel that biomedicine the future of the industry's prospects are very good. Mainly because under the influence of the epidemic, the development of this kind of industry can quickly get a vast improvement.

According to the relevant information on the network indicates that in the late night of May 24, China Biopharmaceutical announcement released a relevant announcement, from March 30, 2021 to the current three-month period, the group harvested to the Renminbi, about 7.243 billion yuan, it can be said that compared with the same period of time growth of about 16.4%, attributable to the parent company holders of the earnings of about the Renminbi on the more than one billion RMB. This kind of revenue makes people very shocked about this, and also makes many investors remain very optimistic about the future prospects of the biopharmaceutical industry.

In fact, many people now have such an attitude is very normal, because according to the information related to this company shows that in the first quarter, the company's legitimate earnings have reached 1.476 billion yuan, which can be said that the same period in the previous year in only 2.4931 million yuan in the case of the growth of a very large margin, and now in the international new Crown disease is still very serious, many countries are therefore still cagey. Serious, many countries are therefore still shrouded in such an epidemic, so the future of the biomedical industry, such as this is definitely very considerable, can bring greater development.

But investors in the assessment of such an industry, or to have their own relevant judgment, after all, everything is just an inference, and some market participants believe that the possibility of this performance is a one-time income, simply can not carry out the relevant valuation, although now there are also a number of research institutes believe that the vaccine vaccination demand is very large, the commercialization of the ability to get enough to redeem, but the editorial staff wants to said it is still very difficult.